Jubilant Therapeutics Inc, a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, has added new members to the company's Scientific Advisory Board, it was reported on Tuesday.

The company has added Julian Downward, PhD, associate research director, Division of Molecular Pathology at the Institute of Cancer Research at the Francis Crick Institute; William C Hahn, MD, PhD, chief scientific officer, William Rosenberg professor of Medicine at the Dana-Farber Cancer Institute and Ross Levine, MD, chief, Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center, to its team.

Syed Kazmi, president and chief executive officer of Jubilant Therapeutics Inc, said, 'We are pleased to welcome these distinguished experts to our Scientific Advisory Board. The depth of their collective expertise and experience will be extremely valuable as we work to progress our programs towards the clinic. We look forward to collaborating with these highly skilled and imaginative scientists.'